Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.7
3.5
Journals
Viruses
Special Issues
Pharmacology of Antiviral Drugs, 2nd Edition
share announcement

Pharmacology of Antiviral Drugs, 2nd Edition

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".

Deadline for manuscript submissions: 28 February 2026 | Viewed by 1743

Special Issue Editor

Dr. David E. Martin

E-Mail Website
Guest Editor
Inc, Jacksonville, FL, USA
Interests: antiviral; influenza virus; repurposed; respiratory syncytial virus (RSV); respiratory virus; RSV; SARS-CoV-2; therapeutic
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Viral infections cause significant morbidity and mortality across the globe in both humans and animals. As the world emerges from the latest viral pandemic, it is clear that considerable work remains to identify and characterize new antiviral treatments. We therefore invite submissions for our upcoming Special Issue on the pharmacology of antiviral drugs. This special issue aims to explore and elucidate the intricate pharmacological aspects of antiviral medications. Researchers and experts are encouraged to contribute original research articles, reviews, and short communications that delve into various aspects of antiviral pharmacology. We welcome submissions that cover a wide range of topics, including, but not limited to, molecular interactions between drugs and viral targets, pharmacokinetics, pharmacodynamics, and the influence of host factors on drug efficacy. Additionally, we seek contributions addressing emerging topics such as drug resistance, novel drug delivery approaches, and advancements in medicinal chemistry to optimize antiviral treatment strategies in humans and animals.

Join us in advancing our understanding of antiviral pharmacology and shaping the future of antiviral therapy. Submit your contributions to this Special Issue to contribute to the global effort in combating viral infections and improving public health outcomes.

Dr. David E. Martin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacology
  • clinical pharmacology
  • antiviral therapy
  • antiviral prophylaxis
  • human viruses
  • animal viruses
  • pharmacokinetics
  • pharmacodynamics
  • drug resistance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

8 pages, 927 KB  
Brief Report
Evaluation of Probenecid Against Filovirus Replication in Vero E6 Cells
by Kendra Alfson, Ricardo Carrion, Jr., Ralph A. Tripp, Chris Cirimotich and David E. Martin
Viruses 2026, 18(1), 43; https://doi.org/10.3390/v18010043 - 26 Dec 2025
Viewed by 227
Abstract
In human and non-human primates, filoviruses, e.g., Ebolaviruses, cause severe hemorrhagic fever for which there are few therapeutic options. While there are licensed vaccines and therapeutics for Ebola virus disease, there is no approved vaccine or treatment for other Ebola diseases. There is [...] Read more.
In human and non-human primates, filoviruses, e.g., Ebolaviruses, cause severe hemorrhagic fever for which there are few therapeutic options. While there are licensed vaccines and therapeutics for Ebola virus disease, there is no approved vaccine or treatment for other Ebola diseases. There is a need for broad-spectrum antivirals to treat Ebola virus (EBOV), Sudan virus (SUDV), and Marburg virus (MARV). We have previously demonstrated that probenecid, an FDA-approved drug with a safety profile spanning over 7 decades, is safe and effective in preventing the replication of influenza A viruses, SARS-CoV-2, and other RNA respiratory viruses, such as HMPV and RSV, both in vitro and in vivo. In this study, probenecid was shown to inhibit the replication of infectious EBOV, SUDV, and MARV in Vero E6 cells, with IC50 Values of 3 μM, 8 μM, and 13 μM, respectively. It also reduced plaque size in infected Vero cell lawns, suggesting reduced virus spread. These studies show that probenecid is an effective, broad-spectrum, host-directed antiviral drug. Full article
(This article belongs to the Special Issue Pharmacology of Antiviral Drugs, 2nd Edition)
►▼ Show Figures

Figure 1

8 pages, 776 KB  
Case Report
Emergence of Bictegravir Resistance in a Treatment-Experienced PWH on Functional Monotherapy and Rapid Replacement by an Ancient Wild-Type Strain Following Transient Treatment Interruption
by Pietro B. Faré, Gabriela Ziltener, Judith Bergadà Pijuan, Irene A. Abela, Britta L. Hirsch, Michael Huber, Johannes Nemeth and Huldrych F. Günthard
Viruses 2025, 17(5), 699; https://doi.org/10.3390/v17050699 - 13 May 2025
Cited by 1 | Viewed by 1192
Abstract
A treatment-experienced, highly adherent person living with HIV for over 25 years developed resistance mutations against all four major ART classes, including bictegravir (BIC). This led to viral failure on a quadruple regimen including BIC and doravirine (DOR). Resistance emergence was associated with [...] Read more.
A treatment-experienced, highly adherent person living with HIV for over 25 years developed resistance mutations against all four major ART classes, including bictegravir (BIC). This led to viral failure on a quadruple regimen including BIC and doravirine (DOR). Resistance emergence was associated with M184V, thymidine analog mutations (TAMs), NNRTI mutations (108I, 234I, 318F), and INSTI mutations (T97A, G140S, Q148H, G149A), likely driven by suboptimal BIC levels due to divalent cation interactions. During a two-month ART interruption, the resistant virus was rapidly replaced by an ancient wild-type strain. Despite resistance to all four ART classes, a genotype-adapted salvage regimen, including fostemsavir, achieved viral suppression within seven months. Full article
(This article belongs to the Special Issue Pharmacology of Antiviral Drugs, 2nd Edition)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop